Home Cart Sign in  
Chemical Structure| 552-58-9 Chemical Structure| 552-58-9

Structure of Eriodictyol
CAS No.: 552-58-9

Chemical Structure| 552-58-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Eriodictyol, a flavonoid isolated and purified from the fruits of Citrus sinensis (L.) Osbeck with anti-inflammatory and antioxidant activities, may possess antidiabetic properties through increasing glucose uptake and improving insulin resistance and be a potential therapeutic resource for Atopic dermatitis and an adjunctive agent to control itchiness in Atopic dermatitis.

Synonyms: Huazhongilexone; 2S-Eriodictyol; (+)-Eriodictyol

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Eriodictyol

CAS No. :552-58-9
Formula : C15H12O6
M.W : 288.25
SMILES Code : O=C1C[C@@H](C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C13
Synonyms :
Huazhongilexone; 2S-Eriodictyol; (+)-Eriodictyol
MDL No. :MFCD00135890
InChI Key :SBHXYTNGIZCORC-ZDUSSCGKSA-N
Pubchem ID :440735

Safety of Eriodictyol

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Eriodictyol

DNA

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
LoVo (colon cancer) 100.68 ±10.86 µM 72 hours low antiproliferative activity Antioxidants (Basel). 2019 Jul 7;8(7):210
MCF7 (breast carcinoma) 150.70 ±9.31 µM 72 hours low antiproliferative activity Antioxidants (Basel). 2019 Jul 7;8(7):210
ARPE-19 cells 50 μM 0, 2, 4, 6, 8 hours Eriodictyol induces nuclear translocation of Nrf2 within 2 hours, reaches a maximum by 4 hours, and remains elevated at 8 hours. HO-1 expression begins within 2 hours after Nrf2 activation and reaches a maximum by 6–8 hours. NQO-1 expression also shows a time-dependent increase. Invest Ophthalmol Vis Sci. 2009 May;50(5):2398-406
ARPE-19 cells 0–100 μM 2 hours or overnight Eriodictyol induces the nuclear translocation of Nrf2 in a dose-dependent manner and increases the expression of HO-1 and NQO-1. Invest Ophthalmol Vis Sci. 2009 May;50(5):2398-406
HT-22 cells 0, 1, 2, 4, 8, 16 μM 48 hours To evaluate the protective effect of Eriodictyol against Aβ1–42 oligomer-induced cytotoxicity in HT-22 cells. Results showed that Eriodictyol significantly increased cell viability and reduced Aβ1–42-induced cell death. Mol Med. 2022 Jan 29;28(1):11
MG63 cells 26.11 μM 48 hours To evaluate the anti-proliferative and pro-apoptotic effects of eriodictyol on MG63 cells. Results showed that eriodictyol significantly inhibited cell proliferation and promoted apoptosis. J Nanobiotechnology. 2025 Feb 14;23(1):109
U2OS cells 27.39 μM 48 hours To evaluate the anti-proliferative and pro-apoptotic effects of eriodictyol on U2OS cells. Results showed that eriodictyol significantly inhibited cell proliferation and promoted apoptosis. J Nanobiotechnology. 2025 Feb 14;23(1):109
ACE2-expressing HEK-293 T cells 88 ~ 126 μM 2 days Suppressed the cellular entry of SARS-CoV-2 S-Vpp variants Cell Biosci. 2023 Jun 28;13(1):118
Beas 2B lung epithelial cells 50 μM 2 days Inhibited TMPRSS2 protein expression Cell Biosci. 2023 Jun 28;13(1):118
MCF 10A (breast cells) 146.61 ±36.21 µM 72 hours low antiproliferative activity Antioxidants (Basel). 2019 Jul 7;8(7):210
DU 145 (prostate cancer) 120.66 ±18.45 µM 72 hours low antiproliferative activity Antioxidants (Basel). 2019 Jul 7;8(7):210
HLMEC (lung microvascular endothelial cells) 25.81 ±6.71 µM 72 hours antiproliferative activity against HLMEC cells Antioxidants (Basel). 2019 Jul 7;8(7):210
LoVo/DX (colon cancer doxorubicin-resistant) 99.22 ±12.46 µM 72 hours low antiproliferative activity Antioxidants (Basel). 2019 Jul 7;8(7):210

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
APP/PS1 transgenic mice Alzheimer’s disease model Intraperitoneal injection 50 mg/kg Three times a week for 3 months To evaluate the ameliorative effect of Eriodictyol on cognitive dysfunction in APP/PS1 mice. Results showed that Eriodictyol significantly improved spatial learning and memory functions, reduced Aβ aggregation, and suppressed Tau hyperphosphorylation. Mol Med. 2022 Jan 29;28(1):11
Nude mice Subcutaneous osteosarcoma model Tail vein injection 5 mg/kg Every other day, 8 times in total To evaluate the anti-tumor effects of eriodictyol in vivo. Results showed that eriodictyol significantly inhibited tumor growth without obvious organ injury. J Nanobiotechnology. 2025 Feb 14;23(1):109

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03482401 Breast Cancer Not Applicable Active, not recruiting June 1, 2019 Spain ... More >> Hospital General Universitario Reina Sofía Murcia, Spain, 30003 Less <<
NCT02627547 Healthy Not Applicable Completed - United Kingdom ... More >> University of Glasgow School of Medicine Glasgow, United Kingdom Less <<
NCT03215043 Pre Diabetes Not Applicable Recruiting June 28, 2019 Brazil ... More >> Sao Paulo State University "Julio de Mesquita Filho", Faculdade de Ciências Farmacêuticas Recruiting Araraquara, Sao Paulo, Brazil, 14800-903 Contact: Thais B Cesar, Ph.D.    +55 16 3301-6927    tcesar@fcfar.unesp.br Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.47mL

0.69mL

0.35mL

17.35mL

3.47mL

1.73mL

34.69mL

6.94mL

3.47mL

References

 

Historical Records

Categories